Gapping up
In reaction to strong earnings/guidance:
- FORM +5.3%, LL +2.8%, DAL +1.9% (guidance) MESA +1.5%
Other news:
- AMRX +22.7% (receives abbreviated new drug application approval for EluRyng, the first generic NuvaRing)
- LMPX +15.5% (Pres/CEO disclosed the purchase of ~132K shares worth ~$1.7 mln)
- FTSV +4.8% (prices underwritten public offering of 4.86 mln shares of its common stock at a price to the public of $35.00 per share)
- PBYI +2.4% (presents results from ongoing Phase II clinical trial of neratinib)
- YRCW +2% (YRC Worldwide announces departure of CFO Stephanie Fisher; appoints Jamie Pierson as CFO and Matt Doheny as Chairman; provides quarter-to-date operating data)
- LVGO +1.9% (prices underwritten public offering of 2,777,327 shares of its common stock by certain selling stockholders at a price of $27.00 per share)
- WPP +1.7% (announces up to GBP 300 mln share repurchase agreement)
- PRVB +1.7% (continues to expect that it will commence a rolling BLA submission for PRV-031 in the middle of 2020)
- CVA +1.4% (signs concession agreement for construction and operation of new Energy-from-Waste facility in China)
- FCAU +1.3% (Fiat Chrysler confirms ratification of four-year collective bargaining agreement)
Analyst comments:
- AMRS +8.6% (initiated with a Outperform at Oppenheimer; tgt $8)
- SWAV +3.9% (upgraded to Overweight from Equal Weight at Wells Fargo)
- MODN +2.3% (upgraded to Overweight from Neutral at JP Morgan)
- GE +2.1% (coverage assumed/upgraded to Buy from Neutral at UBS)
- BHC +2% (upgraded to Overweight from Neutral at JP Morgan)
- HUYA +1.9% (initiated with a Buy at Needham)
- SBUX +1.7% (upgraded to Overweight from Neutral at JP Morgan)
- OII +1.5% (upgraded to Outperform from In-line at Evercore ISI)
- SNPS +1.5% (upgraded to Overweight from Neutral at JP Morgan)
- GMED +1% (upgraded to Overweight from Equal Weight at Wells Fargo)
- KR +0.8% (upgraded to Outperform from In-line at Evercore ISI)
- HSBC +0.6% (upgraded to Buy from Neutral at BofA/Merrill)